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Background: In in vitro fertilization (IVF) and intracytoplasmatic sperm injection (ICSI) treatment a large drop is
present between embryo transfer and occurrence of pregnancy. The implantation rate per embryo transferred is
only 30%. Studies have shown that minor intrauterine abnormalities can be found in 11–45% of infertile women
with a normal transvaginal sonography or hysterosalpingography. Two randomised controlled trials have indicated
that detection and treatment of these abnormalities by office hysteroscopy after two failed IVF cycles leads to a
9–13% increase in pregnancy rate. Therefore, screening of all infertile women for intracavitary pathology prior to
the start of IVF/ICSI is increasingly advocated. In absence of a scientific basis for such a policy, this study will assess
the effects and costs of screening for and treatment of unsuspected intrauterine abnormalities by routine office
hysteroscopy, with or without saline infusion sonography (SIS), prior to a first IVF/ICSI cycle.
Methods/design: Multicenter randomised controlled trial in asymptomatic subfertile women, indicated for a first
IVF/ICSI treatment cycle, with normal findings at transvaginal sonography. Women with recurrent miscarriages, prior
hysteroscopy treatment and intermenstrual blood loss will not be included. Participants will be randomised for a
routine fertility work-up with additional (SIS and) hysteroscopy with on-the-spot-treatment of predefined
intrauterine abnormalities versus the regular fertility work-up without additional diagnostic tests. The primary study
outcome is the cumulative ongoing pregnancy rate resulting in live birth achieved within 18 months of IVF/ICSI
treatment after randomisation. Secondary study outcome parameters are the cumulative implantation rate;
cumulative miscarriage rate; patient preference and patient tolerance of a SIS and hysteroscopy procedure. All data
will be analysed according to the intention-to-treat principle, using univariate and multivariate logistic regression
and cox regression. Cost-effectiveness analysis will be performed to evaluate the costs of the additional tests as
routine procedure. In total 700 patients will be included in this study.
Discussion: The results of this study will help to clarify the significance of hysteroscopy prior to IVF treatment.
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Despite the numerous advances in the field of in vitro
fertilisation (IVF) and intracytoplasmic sperm injection
(ICSI), the maximum implantation rate per embryo
transferred is still approximately 30%. Even if both ovum
pick-up and fertilization occur successfully in the
process of IVF, there is a large unexplained gap between
successful embryo transfer and occurrence of pregnancy.
Implantation failure presents a major clinical challenge
and is a cause of considerable stress to patients and clin-
icians in assisted reproductive technology (ART). Besides
the psychological and physical burden of each IVF treat-
ment cycle, it also adds to the considerable costs asso-
ciated with fertility treatment [1]. If progress is to be
made in improving implantation rates, a greater under-
standing of the factors which determine successful im-
plantation is required.
Implantation failure could be due to the embryo, uter-
ine environment or a combination of both. Even minor
uterine cavity abnormalities, such as endometrial polyps,
small submucous myomas, adhesions, and septa are con-
sidered to have a negative impact on the chance to con-
ceive through IVF [2]. The prevalence of unsuspected
intrauterine abnormalities, diagnosed by hysteroscopy
prior to IVF, has been reported to be 11–45% [3-13].
Therefore, it has been proposed that these abnormalities
should be diagnosed and treated in order to optimize
the condition of the uterine environment and thus the
outcome of IVF treatment. However, this recommenda-
tion is not based on high quality evidence [3,5,7-10]. In
addition, the benefits of hysteroscopy in patients who
will undergo a first IVF/ICSI treatment have not yet
been investigated.
At present, the basic work-up for evaluation of the
uterine cavity prior to IVF consists of transvaginal ultra-
sound, possibly followed by saline infusion sonography
(SIS), hysterosalpingography (HSG) or hysteroscopy. The
accuracy of HSG in assessment of the uterine cavity in-
tegrity in subfertile patients has been reported to be ra-
ther disappointing [14,15]. SIS is increasingly considered
to be useful in diagnosing intrauterine abnormalities. It
is an inexpensive, non-invasive diagnostic test, and has
been proven to be very accurate [16,17]. Yet hystero-
scopy is still considered to be the gold standard. It has
become easy to perform in an outpatient clinic without
anesthesia. Moreover, hysteroscopy enables diagnosis
and treatment of intrauterine pathology in the same
setting.
The NVOG (Dutch society of Obstetrics and Gynae-
cology) as well as the ESHRE (European Society for
Human Reproduction and Embryology) and RCOG
(Royal College of Obstetricians and Gynaecologists) do
not recommend SIS nor hysteroscopy as initial investiga-
tion prior to starting IVF [18-20]. It has been arguedthat the significance of treating unsuspected intrauterine
abnormalities has not yet been proven.
So far, none of the guidelines considered the most re-
cent literature on this topic. In a retrospective cohort
analysis, Gera et al. compared the pregnancy rate after
operative hysteroscopy of patients with intrauterine ab-
normalities at SIS to the pregnancy rate of patients with
a normal uterine cavity. A 31.6% increase in pregnancy
rate was observed after treatment of detected abnormal-
ities [21]. Furthermore, two randomized trials reported
exceptional improvements in pregnancy rates after office
hysteroscopy and instant treatment of detected path-
ology in patients after two failed IVF attempts. Interven-
tion resulted in a 9–13% increase in clinical pregnancy
rate in the subsequent IVF cycle [7,9]. These results
endorsed the findings of other, previously published pro-
spective studies [3,5]. Despite some methodological weak-
nesses in the study design, the results of these studies
indicate a trend towards a beneficial effect of screening
hysteroscopy on IVF outcome. This finding, combined
with the observed high prevalence of intrauterine abnor-
malities, has led to a general debate on the beneficial effect
of pre-IVF work-up of the uterine cavity.
The current study aims to clarify the additive value of
routine SIS and/or hysteroscopy prior to IVF/ICSI . Also,
patient preferences and the cost-effectiveness of these
tests as routine procedures for assessment of the uterine
cavity prior to starting IVF will be assessed.
Methods
Study design
The inSIGHT trial is a multicenter randomised con-
trolled trail (RCT). A total of twenty-five academic and
non-academic centers in the Netherlands will partici-
pate. An economic analysis is incorporated to assess the
cost-effectiveness of the investigated tests as routine pro-
cedures prior to IVF. Inclusion was started in May 2011.
This study will be conducted according to the princi-
ples of the Declaration of Helsinki and in accordance
with the Medical Research Involving Human Subjects
Act (WMO). The study protocol has been approved by
the medical ethical review committee of the University
Medical Center Utrecht (MEC 10–272) and by the board
of directors of all participating centers. The protocol is
registered at clinicaltrial.gov NCT01242852.
Recruitment, consent and randomisation
Women with an indication for a first IVF/ICSI treatment
cycle will be informed about this trial by their attending
physician. They will also receive written patient informa-
tion. One to two weeks after the first visit, the coordin-
ating investigator will counsel the woman. If a woman
agrees to participate in the study, informed consent will
be obtained and randomisation will be performed for
Smit et al. BMC Women's Health 2012, 12:22 Page 3 of 6
http://www.biomedcentral.com/1472-6874/12/22one of two strategies: routine infertility work-up fol-
lowed by immediate IVF (control arm) or the routine
work-up with additional diagnostic tests ((SIS and) hys-
teroscopy) with on-the-spot treatment of intrauterine
pathology followed by IVF (intervention arm) (Figure 1).
Randomisation will be performed centrally by a web-
based randomisation program and will be stratified
according to recruiting center.
Study population
All women with primary or secondary infertility
scheduled for a first IVF/ICSI treatment cycle at one
of the participating hospitals who have a normal
transvaginal ultrasound are considered to be eligible
for inclusion. A normal transvaginal ultrasound is
defined as no visible intracavitary pathology (e.g. sub-
mucous myomas, polyps or septa) and will be per-
formed in the follicular phase of the menstrual cycle.
Intramural myomas without impression or deform-
ation of the uterine cavity are incorporated in the
definition of a normal ultrasound. Exclusion criteria
are recurrent miscarriage, defined as 2 or more mis-
carriages prior to the 20th week of gestation, prior
hysteroscopy treatment and intermenstrual blood loss.
Interventions
Intervention arm
All women in the intervention group will undergo rou-
tine fertility work-up with additional tests. In five of theAsymptomatic subfertile women with n    
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Figure 1 Flowchart inSIGHT study.twenty-five research hospitals the additional tests consist
of SIS and hysteroscopy. In all the other participating
hospitals the additional test will consist of solely a
hysteroscopy.
SIS will be performed prior to the hysteroscopy on CD
3–9. A speculum will be inserted vaginally and up to
20 ml of sterile saline solution will be infused into the
uterine cavity through a catheter to distend the endo-
metrial cavity. A transvaginal transducer will be used to
scan the uterine cavity. The findings at SIS will be
recorded in a standardised manner on the case record
form (CRF).
The hysteroscopy examination will be scheduled in the
early-mid follicular phase of a menstrual cycle (day 3–12).
The hysteroscopy examinator will be blinded for SIS out-
comes. A vaginoscopic approach will be used without
anesthesia in an outpatient setting. Only if the examin-
ation cannot be accomplished due to patient intolerance,
the possibility of a paracervical block will be offered. Hys-
teroscopy will be performed using a 5-mm outer-diameter
continuous flow hysteroscope with a 5 French working
channel and a 30 direction of view. The uterine cavity will
be distended by saline infusion. The endocervical canal,
uterine cavity, tubal orifices and endometrium will
be inspected methodically and findings recorded on
a standardized form. Intrauterine abnormalities will
be defined as endometrial polyps, septate uterus,
adhesions and chronic or acute endometritis. A
sample of the endometrium will be obtained forormal TVS 
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‘pipelle’ biopsy canulla or grasping forceps. Thera-
peutic hysteroscopy will be performed in the same
hysteroscopy session if any of the predefined intra-
uterine abnormalities is detected. It is left to the
judgement of the operator physician to decide to
perform a septum resection in a subsequent session
with laparoscopic observation. After the hystero-
scopy, the resected tissue will be examined histologi-
cally by a pathologist for the presence of chronic or
acute endometritis.
To assess patient tolerance of SIS and a diagnostic/thera-
peutic hysteroscopy, all patients will be asked to complete a
standardized questionnaire, containing questions about the
level of tolerance and acceptability of both procedures.
Control arm
All women allocated to the control group will be sched-
uled for IVF or ICSI and undergo standard treatment,
without SIS or hysteroscopy.
Fertility treatment
All randomised women, be it allocated to intervention
or control arm, will undergo IVF. In the intervention
group IVF treatment will be started within 3 months
after hysteroscopy. Rec-FSH or HMG combined with a
GnRH agonist protocol (Leuprolide or Triptorelin 100
microgram) or a GnRH antagonist protocol (Ganirelix/
Cetrorelix 0.25 mg/d) will be used. Final oocyte matur-
ation will be achieved by the administration of HCG
when 3 or more follicles of more than 16 mm are
present. Oocyte retrieval will be carried out 36 hours
after HCG administration. Luteal phase supplementation
consists of 600 mg natural micronised progesterone in
three separate dosages (UrogestanW/ProgestanW 100 mg
3x2/day) starting in the evening after oocyte retrieval
and continued until 18 days after ovum pick-up.
Withdrawal of individual patients
Subjects can abandon the study at any time for any rea-
son if they wish to do so without any consequences. The
investigator can decide to withdraw a subject from the
study for urgent medical reasons.
Outcome measures
The primary endpoint of this study will be the cumula-
tive ongoing pregnancy rate resulting in live birth
achieved within 18 months of IVF/ICSI treatment after
randomisation.
Secondary study parameters/endpoints will be the cu-
mulative implantation and miscarriage rate within
18 months of IVF/ICSI treatment after randomisation,
cost calculations of SIS, hysteroscopy procedures and
the IVF treatment, patient preference and tolerance ofSIS and diagnostic/therapeutic hysteroscopy procedure
and presence of unexpected intracavitary abnormalities
(e.g. endometrial polyps, septate uterus, adhesions and
endometritis) prior to IVF/ICSI.
To investigate the cost-effectiveness of SIS and hys-
teroscopy as routine procedures prior to IVF treatment,
a cost analysis will be performed. The economic evalu-
ation is performed from a societal perspective. Differen-
tiation will be made between direct medical costs (all
health care sector costs), direct non-medical costs (costs
outside the health care sector that are affected by health
status or health care) and indirect costs of the fertility
treatment (costs of sick leave due to fertility treatment).
For medical costs, the process of care is divided into
three cost stages (cost of SIS, cost of hysteroscopy, cost
of IVF treatment), which can reoccur in case of repeat
treatment cycles. Costs will be computed from the
period of inclusion to the end of follow-up (18 months).
Health care utilisation in the fertility treatment con-
sists of visits to hospital, ultrasound, gonadotrophins,
oocyte retrieval, lab work of IVF (including various la-
boratory tests) and hospital care. Volumes of health care
resources use will be measured prospectively alongside
the clinical study. At this stage, direct non-medical and
indirect costs may be generated if women are absent
from paid work, either for visiting the fertility clinic dur-
ing IVF treatment, or for sick leave associated with phys-
ical or psychological side-effects of this treatment. The
Health and Labor Questionnaire [22] will be used to
document absence from paid work.Statistical analysis
Sample size calculation
Based on the literature, the increase in ongoing pregnancy
in women with recurrent IVF failure after treatment of
predefined abnormalities of the uterine cavity is found to
be 9–32% in the subsequent IVF/ICSI cycles [5,7,9].
In a group of women indicated for a first IVF/ICSI
treatment cycle, the difference in cumulative live birth
rate after 18 months of IVF/ICSI treatment is estimated
to be 10% between the patients with and without hys-
teroscopy (40% versus 30%). The number of patients
needed to have 80% power (with alpha = 0.05) to detect
such a difference is 350 per study arm.
To be able to answer the question on the benefit of
using SIS as a pre-selection tool the following sample
size calculation for patients needing to have both SIS
and hysteroscopy was made. From previous literature,
the prevalence of unsuspected intrauterine abnormalities
is considered to be 12% and the sensitivity of SIS com-
pared to hysteroscopy to be 95% [11]. SIS and hystero-
scopy need to be performed in 160 women to achieve a
95% confidence interval of 10% (85–100%). This means
Smit et al. BMC Women's Health 2012, 12:22 Page 5 of 6
http://www.biomedcentral.com/1472-6874/12/22that a total of 320 women need to be randomised in the
five hospitals in this study that perform SIS.
Economic analysis
For each strategy, live birth rate as well as the average
costs per patient will be estimated and used to calculate
cost-effectiveness ratios. Incremental cost-effectiveness
ratios will be estimated for two strategies of additional
diagnostic/therapeutic procedures: SIS followed by hys-
teroscopy if SIS is abnormal or no SIS but direct hys-
teroscopy. These two strategies will be compared to no
additional investigations (routine fertility investigation
followed directly by IVF/ICSI). Robustness of the results
(costs and health outcomes) for various assumptions
and parameters estimates will be explored in sensitivity
analyses and visualized in ICER-graphs and cost-
effectiveness acceptability curves.
Statistic analysis
SPSS and Excel will be used to perform the statistical
analysis. A probability less than 0.05 will be considered
to be significant. Data will be presented for the two arms
of the study group. Data will be expressed as means +/−
standard deviation and proportions or rates. The analysis
will be by intention to treat.
Descriptive analysis will be used to assess the preva-
lence of predefined minor intrauterine abnormalities at
SIS and office hysteroscopy. Comparisons between the
two arms of the randomised group will be done by ap-
plying Chi-square testing to crude rates of cumulative
implantation and ongoing pregnancy and by using life
table analysis to account for the factor of time to im-
plantation or pregnancy. The difference in tolerability of
SIS will be compared to the tolerability of diagnostic and
therapeutic hysteroscopy making use of the Student’
t-test analysis of the VAS score.
The relative contribution of predefined cavitary abnor-
malities versus other predictive factors like female age
and duration of infertility will be assessed by univariate
and multivariate logistic regression and Cox regression.
Discussion
Despite the great advances in the field of IVF/ICSI, im-
plantation failure is still high. This not only causes con-
siderable stress to the woman but is also associated with
high costs of the fertility treatment. The uterine cavity is
considered to play an important role in successful im-
plantation. Even minor abnormalities, such as endomet-
rial polyps, submucous myomas, adhesions or septa, are
thought to impair the chance to conceive [2]. Studies
have shown a high prevalence of unsuspected intrauter-
ine abnormalities prior to IVF [3-12,23]. In addition, two
RCTs reported improvement in pregnancy rates after
hysteroscopy in the subsequent IVF cycle in patientswith two previous failed IVF attempts. Currently, hys-
teroscopy is not recommended as routine investigation
in the fertility work-up because of a lack of robust evi-
dence. The present inSIGHT study is a large randomised
controlled trial in which the effects on pregnancy rates
and costs of SIS and hysteroscopy will be studied. The
results of this study, which are expected in 2015, will
help to clarify the significance of hysteroscopy prior to
IVF/ICSI treatment.
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